CN106636033A - Improved cell-free synthesis system and application thereof - Google Patents
Improved cell-free synthesis system and application thereof Download PDFInfo
- Publication number
- CN106636033A CN106636033A CN201611259561.9A CN201611259561A CN106636033A CN 106636033 A CN106636033 A CN 106636033A CN 201611259561 A CN201611259561 A CN 201611259561A CN 106636033 A CN106636033 A CN 106636033A
- Authority
- CN
- China
- Prior art keywords
- skeletal muscle
- tyrosine kinase
- receptor tyrosine
- final concentration
- precipitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 15
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 15
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 27
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract description 24
- 241000588724 Escherichia coli Species 0.000 claims abstract description 22
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 17
- 239000013612 plasmid Substances 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 238000005119 centrifugation Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 239000007984 Tris EDTA buffer Substances 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 238000005457 optimization Methods 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 108700010070 Codon Usage Proteins 0.000 claims description 3
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims description 3
- 102100034866 Kallikrein-6 Human genes 0.000 claims description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- -1 dexycholate Chemical compound 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000006194 liquid suspension Substances 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 108700005078 Synthetic Genes Proteins 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000014616 translation Effects 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 238000010367 cloning Methods 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical class [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical class [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses an improved cell-free synthesis system, which comprises improvement of a supply reagent. In addition, the invention further discloses an application of an improved cell-free synthesis system in the synthesis of skeletal muscle receptor tyrosine kinase. The application comprises the following steps: (1) synthesizing and cloning of a skeletal muscle receptor tyrosine kinase gene; (2) building of recombinant plasmids; (3) preparing of an escherichia coli S30 extract; (4) semi-continuous cell-free protein synthesis reaction; and (5) deposition treatment. An improved cell-free synthesis method is adopted, the improved cell-free synthesis system can be used for in vitro synthesis of the skeletal muscle receptor tyrosine kinase and the expression efficiency is improved.
Description
Technical field
The invention belongs to albumen preparing technical field, and in particular to a kind of improved cell free translation system and its application.
Background technology
Natural inner membrane protein matter is present in biomembranous lipid environment, but at present the technology of research inner membrane protein matter is
They are dispersed in the environment of the aqueous solution first, are operated with reference to the method for water soluble protein.In order to effectively study
Inner membrane protein matter, it is necessary premise to be dissolved in water environment.Cause inner membrane protein typically by addition detergent at present
Matter and lipid form soluble compound to complete in water.The dissolving of inner membrane protein matter is a rough process
, often there is protein denaturation and/or aggregation in the process in journey.Loss and inactivation in order to avoid protein, the process
Extreme care is needed during optimization.Therefore course of dissolution is the step of processing the most critical of memebrane protein.
Skeletal muscle receptor tyrosine kinase (MuSK) is a kind of antigen protein being present in mammal body, and skeletal muscle is received
Body EGFR-TK is a kind of transmembrane protein related to acetylcholinergic receptor, in the development of skeletal muscle, skeletal muscle acceptor junket
Histidine kinase be when setting up postsynaptic membrane set up major synaptic skeleton primary requirement, myasthenia gravis (myasthenia
Gravis, MG) it is a kind of autoimmune disease being caused by autoantibody, involving neuromuscular junction (NMJ), muscle
Specificity kinase antibody (MuSKAb) plays critically important effect in the onset and PD in myasthenia gravis. closes at present
Effect in skeletal muscle receptor tyrosine kinase antibody in myasthenia gravis is still one of focus for studying in the world, the research
But there is certain demand to skeletal muscle receptor tyrosine kinase. the albumen is difficult expression in common expression system,
Due to stronger hydrophobicity, almost do not express.
The content of the invention
The invention aims to solve the above problems and provide.
The present invention is achieved through the following technical solutions：
1. the synthesis of skeletal muscle receptor tyrosine kinase gene and clone
The cDNA of secretion type expression people's muscle specific kinases is searched from GeneBank, the amino acid of its 24-495AA is taken
Sequence, on the premise of amino acid sequence is not changed, carries out synthesizing base after codon optimization according to e. coli codon preference
Because of sequence.Sequence is shown in sequence table 1, and double enzyme site is introduced respectively to the sequence two ends with PCR method.
2. the structure of recombinant plasmid
The PCR 1.4kb bands glue reclaims that obtain of amplification simultaneously use enzymes double zyme cutting, and carrier pET28a is equally with same interior
Enzyme cutting double digestion, reclaims big fragment.Then connect carrier and purpose fragment with T4DNA ligases, Escherichia coli are converted with it
In DH5 α competent cells.Screening recon obtains recombinant plasmid pET28a-MuSK.
3. the preparation of Escherichia coli S30 extracts
S30 extracts refer to DNA can be transcribed into mRNA and/or by mRNA using S30 buffer solutions from what Escherichia coli were extracted
It is translated as the prepared product of the vitro reactions mixture of polypeptide.The extract is comprising for the biology needed for acellular albumen synthesis
Learn function tRNA, amino acid and ribosomes etc..S30 extracts are it is known in the art that and being described in for example《In Vitro
Synthesis of Protein in Microbial Systems》Geoffrey Zubay,1973.Can be in accordance with the following methods
Obtain Escherichia coli extract.Numerous culture mediums for being suitable to Escherichia coli Growth, such as 2YTPG culture mediums, Ran Houben may be selected
Art personnel are it should be appreciated that many culture mediums can be adapted to this purpose.With suitable cell buffer suspension liquid suspension large intestine bar
Bacterium cell, uses high-pressure homogeneous crusher machine, centrifugation, removes precipitation, obtains Escherichia coli extract.All steps are grasped on ice
Make.Bacterial strain is with BL21 (DE3).
4. semicontinuous acellular albumen synthetic reaction
The semicontinuous acellular albumen synthetic reaction of standard includes following composition：57mM HEPES-KOH (pH8.2),
1.2mM ATP, 0.85mM GTP, 0.85mM UTP, 0.85mM CTP, 0.64mM cAMP, 200mM potassium glutamates, 80mM acetic acid
Ammonium, 15mM magnesium acetates, 34 μ g/mL folinic acid, 6.7 μ g/mL pET28a-MuSK plasmids, 33 μ g/mL T7RNA polymerizations
Enzyme, 20 kinds of amino acid are each 500 μM, 2%PET8000,33mM PEP, and 24% Escherichia coli extract.
For semi-continuous expression system, 300 μ L standard reactions mixtures are loaded on D-TubeTM Dialyzer Midi
In (Thermo, 3.5kDa), 4.5mL supplies reagent (Feeding buffer) is loaded in 50mL Corning centrifuge tubes.By D-
TubeTMDialyzer Midi are put into 50mL centrifuge tubes.Supply reagent does not have template, without t7 rna polymerase, remaining and mark
Quasi- reactant mixture is consistent.Prepare respective reaction liquid and supply liquid, in adding reaction system, 30 DEG C of overnight incubations.Centrifugation, point
From supernatant precipitation, skeletal muscle receptor tyrosine kinase is memebrane protein, because the hydrophobicity of itself, expression is precipitated memebrane protein.
5. precipitation process
Precipitation is resuspended with PBS, centrifugation, removes supernatant, repeats the step 2 time.It is molten with the weak detergents of 1mL 0.5%-1.5%
The resuspended precipitation of liquid, plus a small amount of reducing agent is to final concentration of 5mM.30 DEG C, 220rpm, concussion 1h to precipitation all dissolvings.Centrifugation, takes
Supernatant.Add dispersant to final concentration of 0.2%-2%, 50mM GSSG to final concentration 1-5mM, 100mM GSSH are to final concentration
2-8mM.Centrifuge tube places 4 DEG C, stands 12h.The albumen after standing is taken out, is dialysed in TE buffer solutions 3 days.TE bufferings during dialysis
Fluid exchange 2 times.Centrifugation, obtains supernatant.As final skeletal muscle receptor tyrosine kinase protein solution.
As further, preferably, the S30 buffer solutions include：
Used as further preferably, the weak detergent added in precipitation process is SKL,
Triton X210, octylglucoside, dexycholate, SDS, CTAB, Tween 20, NP40 etc., preferably
SKL, solution concentration is 0.5%.
Used as further preferred, the 50mM GSSG to final concentration 1mM added in precipitation process, 100mM GSSH are to end
Concentration 2mM.
As further preferred, dispersant is added to be PEG 4000 in precipitation process.
As further, preferably, reducing agent is DTT, DTE, GSH, beta -mercaptoethanol etc., preferably DTT.
The invention has the beneficial effects as follows：
(1) skeletal muscle receptor tyrosine kinase protein is expressed using cell-free expression system, overcomes hydrophobic structure expression
Difficult problem, can prepare the protein product that General Expression system can not prepared.
(2) process post-processed using the albumen of acellular high efficient expression, is entered to the albumen precipitation of acellular great expression
The method of renaturation, has prepared the preferable activated protein of immunocompetence after the denaturation of row elder generation, overcomes the low of common acellular expression
Expression and need to add liposome just activated problem.
Description of the drawings
The electrophoretogram of skeletal muscle receptor tyrosine kinase protein prepared by Fig. 1 embodiments one, it is seen that have one obvious at 60kDa
The size of band, size and albumen is basically identical.
The electrophoretogram of skeletal muscle receptor tyrosine kinase protein prepared by Fig. 2 embodiments two, it is seen that have one obvious at 60kDa
The size of band, size and albumen is basically identical.
Specific embodiment
Below in conjunction with the accompanying drawings the present invention is described in further detail with embodiment.Following examples are only exemplary
, only further describe in detail doing to technical scheme, it will be understood by those within the art that,
In the spirit and scope without departing from technical solution of the present invention, the modification or replacement carried out to technical scheme all should be covered at this
In the claims of invention.
Embodiment one
1. the synthesis of skeletal muscle receptor tyrosine kinase gene and clone
The mRNA of secretion type expression people's muscle specific kinases is obtained from gene library, the amino acid of its 24-495AA is taken
Sequence carries out synthetic gene sequence after codon optimization according to e. coli codon preference.Sequence is shown in sequence table 1, with what is synthesized
DNA as pcr template,
Upstream primer is, SEQ ID NO：2
Primer sequence is：5 '-GATCGGATCCCTGCCGAAAGCGCCG-3 ',
Downstream primer is, SEQ ID NO：3
Primer sequence is：5 '-ATG AAGCTTAATATCACGCACATAT-3 ',
The restriction enzyme site of BamH I and Hind III is introduced respectively.PCR reaction conditions:95 DEG C of denaturations 4min, 94 DEG C of denaturation
1min, 52 DEG C of annealing 1min, 72 DEG C of extension 2min, carry out 30 circulations, 72 DEG C of extension 6min.
2. the structure of recombinant plasmid
The PCR 1.4kb bands glue reclaims that obtain of amplification and with restriction endonuclease BamH I and the double digestions of Hind III, carrier pET28a
Equally with BamH I and the double digestions of Hind III, big fragment is reclaimed.Then carrier and purpose fragment are connected with T4 DNA ligases,
Converted in bacillus coli DH 5 alpha competent cell with it.Using LB ampicillin kanamycins plate screenings recombinant conversion,
Picking transformant is bacterium colony PCR, and the conversion daughter colony extraction recombinant plasmid endonuclease digestion of purposeful band is further reflected
Determine, and serve Hai Sheng works Bioisystech Co., Ltd to be sequenced, obtain recombinant plasmid pET28a-MuSK.
3. the preparation of Escherichia coli extract S30
Extract refer to can by DNA be transcribed into mRNA and/or mRNA is translated as polypeptide vitro reactions mixture preparation
Thing.The extract is comprising for the biological function tRNA needed for acellular albumen synthesis, amino acid and ribosomes etc..S30
Extract is it is known in the art that and being described in for example《In Vitro Synthesis of Protein in
Microbial Systems》Geoffrey Zubay,1973.Escherichia coli extract can in accordance with the following methods be obtained.May be selected
Numerous culture mediums for being suitable to Escherichia coli Growth, such as 2YTPG culture mediums, then it will be understood by a person skilled in the art that many
Culture medium can be adapted to this purpose.With suitable cell buffer suspension liquid suspension Bacillus coli cells, high-pressure homogeneous crusher machine is used, from
The heart, removes precipitation, obtains Escherichia coli extract.All steps are operated on ice.Bacterial strain is with BL21 (DE3).
4. semicontinuous acellular albumen synthetic reaction
The semicontinuous acellular albumen synthetic reaction of standard includes following composition：57mM HEPES-KOH (pH8.2),
1.2mM ATP, 0.85mM each of GTP, UTP and CTP, 0.64mM cAMP, 200mM potassium glutamates, 80mM ammonium acetates,
15mM magnesium acetates, 34 μ g/mL folinic acid, 6.7 μ g/mL pET28a-MuSK plasmids, 33 μ g/mLT7RNA polymerases,
500 μM of 20 kinds of amino acid are each 500 μM, 2%PET8000,33mM PEP, and 24% Escherichia coli extract.
For semi-continuous expression system, 300 μ L standard reactions mixtures are loaded on D-TubeTM Dialyzer Midi
In (Thermo, 3.5kDa), 4.5mL supplies reagent (Feeding buffer) is loaded in 50mL Corning centrifuge tubes.By D-
TubeTMDialyzer Midi are put into 50mL centrifuge tubes.Supply reagent does not have template, without t7 rna polymerase, remaining and mark
Quasi- reactant mixture is consistent.
Semi-continuous expression system requires 2 reaction environments, and centre is separated by one and half dialysis membranes, and suitable preparation scale is other
Protein production.Reative cell (Reaction Room) RM includes macromolecule substrate, such as enzyme and nucleic acid.Another supply room
(Feeding Room) FM includes low molecule precursor, such as amino acid, energy production material and nucleotides.FM is by fresh premise
Material introduces RM, while the catabolite for having inhibitory action constantly enters FM from RM.Therefore, semi-continuous expression system yield
Significantly improve, the reaction time extends.Prepare respective reaction liquid and supply liquid, in adding reaction system, 30 DEG C of overnight incubations.From
The heart, separates supernatant precipitation, and skeletal muscle receptor tyrosine kinase is memebrane protein, because the hydrophobicity of itself, expression is memebrane protein
Precipitation.
5. precipitation process
Precipitation is resuspended with PBS, centrifugation, removes supernatant, repeats the step 2 time.With the resuspended precipitation of 1mL 0.5%SKL solution,
Plus DTT to final concentration of 5mM.30 DEG C, 220r, concussion 1h to precipitation all dissolvings.Centrifugation, takes supernatant.Add 20%PEG
4000 to final concentration of 0.2%, 50mM GSSG to final concentration 1mM, 100mM GSSH to final concentration 2mM.Centrifuge tube places 4 DEG C,
Stand 12h.The albumen after standing is taken out, is dialysed in TE buffer solutions 3 days.TE bufferings fluid exchange 2 times during dialysis.Centrifugation, obtains
Supernatant.As final skeletal muscle receptor tyrosine kinase protein solution.
Embodiment two
Step 1-4 as step 1-4 of embodiment one,
5. precipitation process
Precipitation is resuspended with PBS, centrifugation, removes supernatant, repeats the step 2 time.With the resuspended precipitation of 1mL 1.5%SKL solution,
Plus DTT to final concentration of 5mM.30 DEG C, 220rpm, concussion 1h to precipitation all dissolvings.Centrifugation, takes supernatant.Add 20%PEG
4000 to final concentration of 2%, 50mM GSSG to final concentration 5mM, 100mM GSSH to final concentration 8mM.4 DEG C of centrifuge tube placement, it is quiet
Put 12h.The albumen after standing is taken out, is dialysed in TE buffer solutions 3 days.TE bufferings fluid exchange 2 times during dialysis.Centrifugation, obtains
Clearly.As final skeletal muscle receptor tyrosine kinase protein solution.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means to combine specific features, structure, material or spy that the embodiment or example are described
Point is contained at least one embodiment of the present invention or example.In this manual, to the schematic representation of above-mentioned term not
Necessarily refer to identical embodiment or example.And, the specific features of description, structure, material or feature can be any
One or more embodiments or example in combine in an appropriate manner.
Although an embodiment of the present invention has been shown and described, it will be understood by those skilled in the art that：Not
These embodiments can be carried out with various changes, modification, replacement and modification in the case of the principle and objective that depart from the present invention, this
The scope of invention is limited by claim and its equivalent.
<110>Wuhan Jin Kairui bioengineering Co., Ltd
<120>A kind of improved cell free translation system and its application
<130> 2016
<160> 3
<170> PatentIn version 3.3
<210> 1
<211> 1416
<212> DNA
<213> Homo sapiens
<400> 1
ctgccgaaag cgccggtgat taccaccccg ctggaaaccg tggatgcgct ggtggaagaa 60
gtggcgacct ttatgtgcgc ggtggaaagc tatccgcagc cggaaattag ctggacccgt 120
aacaaaattc tgattaaact gtttgatacc cgttatagca ttcgtgaaaa cggccagctg 180
ctgaccattc tgagcgtgga agatagcgat gatggcattt attgctgcac cgcgaacaac 240
ggcgtgggcg gcgcggtgga aagctgcggc gcgctgcagg tgaaaatgaa accgaaaatt 300
acccgtccgc cgattaacgt gaaaattatt gaaggcctga aagcggtgct gccgtgcacc 360
accatgggca acccgaaacc gagcgtgagc tggattaaag gcgatagccc gctgcgtgaa 420
aacagccgta ttgcggtgct ggaaagcggc agcctgcgta ttcataacgt gcagaaagaa 480
gatgcgggcc agtatcgttg cgtggcgaaa aacagcctgg gcaccgcgta tagcaaagtg 540
gtgaaactgg aagtggaaga agaaagcgaa ccggaacagg ataccaaagt gtttgcgcgt 600
attctgcgtg cgccggaaag ccataacgtg acctttggca gctttgtgac cctgcattgc 660
accgcgaccg gcattccggt gccgaccatt acctggattg aaaacggcaa cgcggtgagc 720
agcggcagca ttcaggaaag cgtgaaagat cgtgtgattg atagccgtct gcagctgttt 780
attaccaaac cgggcctgta tacctgcatt gcgaccaaca aacatggcga aaaatttagc 840
accgcgaaag cggcggcgac cattagcatt gcggaatggc gtgaatattg cctggcggtg 900
aaagaactgt tttgcgcgaa agaatggctg gtgatggaag aaaaaaccca tcgtggcctg 960
tatcgtagcg aaatgcatct gctgagcgtg ccggaatgca gcaaactgcc gagcatgcat 1020
tgggatccga ccgcgtgcgc gcgtctgccg catctggcgt ttccgccgat gaccagcagc 1080
aaaccgagcg tggatattcc gaacctgccg agcagcagca gcagcagctt tagcgtgagc 1140
ccgacctata gcatgaccgt gattattagc attatgagca gctttgcgat ttttgtgctg 1200
ctgaccatta ccaccctgta ttgctgccgt cgtcgtaaac agtggaaaaa caaaaaacgt 1260
gaaagcgcgg cggtgaccct gaccaccctg ccgagcgaac tgctgctgga tcgtctgcat 1320
ccgaacccga tgtatcagcg tatgccgctg ctgctgaacc cgaaactgct gagcctggaa 1380
tatccgcgta acaacattga atatgtgcgt gatatt 1416
<210> 2
<211> 25
<212> DNA
<213>Artificial sequence
<400> 2
gatcggatcc ctgccgaaag cgccg 25
<210> 3
<211> 25
<212> DNA
<213>Artificial sequence
<400> 3
atgaagctta atatcacgca catat 25
Claims (8)
1. a kind of improved cell free translation system, it is characterised in that the supply reagent in the cell free translation system is not contained
MRNA templates.
2. a kind of method for preparing skeletal muscle receptor tyrosine kinase, it is characterised in that comprise the following steps that：
(1) synthesis of skeletal muscle receptor tyrosine kinase gene and clone：
The cDNA of secretion type expression people's muscle specific kinases is searched from GeneBank, the amino acid sequence of its 24-495AA is taken
Row, on the premise of amino acid sequence is not changed, according to e. coli codon preference synthetic gene after codon optimization are carried out,
Its nucleotide sequence such as SEQ ID NO:Shown in 1, using the DNA of synthesis as pcr template, design upstream primer and downstream primer,
Double enzyme site is introduced to the gene two ends, enters performing PCR amplification；
(2) structure of recombinant plasmid：
Reclaim the PCR 1.4kb bands glue that obtains of amplification and use enzymes double zyme cutting, carrier pET28a is with same enzymes double zyme
Cut, reclaim big fragment；Connect carrier and purpose fragment with T4DNA ligases, bacillus coli DH 5 alpha competence is converted with it thin
In born of the same parents, screening recon obtains recombinant plasmid pET28a-MuSK；
(3) preparation of Escherichia coli S30 extracts：
E. coli bl21 (DE3) is chosen, with cell buffer suspension liquid suspension Bacillus coli cells, high-pressure homogeneous crusher machine is used,
Centrifugation, removes precipitation, obtains Escherichia coli extract, and all steps are operated on ice；
(4) semicontinuous acellular albumen synthetic reaction：
300 μ L standard reactions mixtures are loaded on into D-TubeTMIn Dialyzer Midi (Thermo, 3.5kDa), 4.5mL supplies
Reagent Feeding buffer are loaded in 50mL Corning centrifuge tubes, by D-TubeTMDialyzer Midi be put into 50mL from
In heart pipe, 30 DEG C of overnight incubations, centrifugation separates supernatant precipitation；
(5) precipitation process：
Precipitation is resuspended with PBS, centrifugation, removes supernatant, repeats the step 2 time, with the weak detergent solution weights of 1mL 0.5%-1.5%
Outstanding precipitation, plus a small amount of reducing agent is to final concentration of 5mM；30 DEG C, 220rpm, concussion 1h take to all dissolvings, centrifugation is precipitated
Clearly；Dispersant is added to final concentration of 0.2%-2%, 50mM GSSG to final concentration 1-5mM, 100mM GSSH to final concentration 2-
8mM；Centrifuge tube places 4 DEG C, stands 12h；The albumen after standing is taken out, is dialysed in TE buffer solutions 3 days；TE buffer solutions during dialysis
Change 2 times, centrifugation obtains supernatant, obtains final skeletal muscle receptor tyrosine kinase protein solution.
3. a kind of improved cell free translation system according to claim 1, it is characterised in that the acellular synthesis system
Supply reagent in system does not contain t7 rna polymerase.
4. a kind of method for preparing skeletal muscle receptor tyrosine kinase according to claim 2, it is characterised in that step
(3) in, the buffer solution is, when cumulative volume is 2000mL:
5. a kind of method for preparing skeletal muscle receptor tyrosine kinase according to claim 2, it is characterised in that step
(5) in, the weak detergent be SKL, Triton X2100, octylglucoside, dexycholate, SDS, CTAB, Tween
One kind in 20, NP40, preferably SKL, solution concentration is 0.5%.
6. a kind of method for preparing skeletal muscle receptor tyrosine kinase according to claim 2, it is characterised in that step
(5) in, the GSSG preferably final concentration of 1mM, the GSSH preferably final concentration of 2mM.
7. a kind of method for preparing skeletal muscle receptor tyrosine kinase according to claim 2, it is characterised in that step
(5) in, the dispersant is PEG 4000.
8. a kind of method for preparing skeletal muscle receptor tyrosine kinase according to claim 2, it is characterised in that step
(5) in, the reducing agent be DTT, DTE, GSH, beta -mercaptoethanol, preferably DTT.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611259561.9A CN106636033A (en) | 2016-12-30 | 2016-12-30 | Improved cell-free synthesis system and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611259561.9A CN106636033A (en) | 2016-12-30 | 2016-12-30 | Improved cell-free synthesis system and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106636033A true CN106636033A (en) | 2017-05-10 |
Family
ID=58837468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611259561.9A Pending CN106636033A (en) | 2016-12-30 | 2016-12-30 | Improved cell-free synthesis system and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106636033A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111378708A (en) * | 2018-12-28 | 2020-07-07 | 康码（上海）生物科技有限公司 | Optimized in-vitro cell-free protein synthesis system and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1609228A (en) * | 2002-12-27 | 2005-04-27 | 株式会社岛津制作所 | Insect cell extract used in cell-free protein synthesis, its preparation and application |
| CN103820405A (en) * | 2014-02-19 | 2014-05-28 | 江南大学 | Method for expression of fatty acid desaturase by acellular protein synthesis system |
| CN106011163A (en) * | 2016-05-19 | 2016-10-12 | 武汉华美生物工程有限公司 | Method for cell-free expression of signal protein and expression system |
-
2016
- 2016-12-30 CN CN201611259561.9A patent/CN106636033A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1609228A (en) * | 2002-12-27 | 2005-04-27 | 株式会社岛津制作所 | Insect cell extract used in cell-free protein synthesis, its preparation and application |
| CN103820405A (en) * | 2014-02-19 | 2014-05-28 | 江南大学 | Method for expression of fatty acid desaturase by acellular protein synthesis system |
| CN106011163A (en) * | 2016-05-19 | 2016-10-12 | 武汉华美生物工程有限公司 | Method for cell-free expression of signal protein and expression system |
Non-Patent Citations (4)
| Title |
|---|
| TAN SINDHUMATE MB ET AL.,: "Homo sapiens muscle associated receptor tyrosine kinase(MUSK), transcript variant 2,mRNA，NM_001166280.1", 《GENBANK》 * |
| 刘亮伟等: "《基因工程原理与实验指导》", 30 September 2010, 中国轻工业出版社 * |
| 刘文雯: "肌肉特异性激酶基因的克隆及在大肠杆菌中的表达", 《中国优秀硕士学位论文全文数据库基础科学辑》 * |
| 马荣荣: "大肠杆菌无细胞合成体系的构建及表达多种蛋白质的研究", 《中国优秀硕士学位论文全文数据库基础科学辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111378708A (en) * | 2018-12-28 | 2020-07-07 | 康码（上海）生物科技有限公司 | Optimized in-vitro cell-free protein synthesis system and application thereof |
| CN111378708B (en) * | 2018-12-28 | 2022-07-19 | 康码（上海）生物科技有限公司 | In-vitro cell-free protein synthesis system and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018171747A1 (en) | In vitro dna-to-protein (d2p) synthesis system, preparation, reagent kit, and preparation method | |
| CN115867324A (en) | Generation of optimized nucleotide sequences | |
| Pierce et al. | Transfer, integration and expression of functional nuclear genes between multicellular species | |
| CN115011616B (en) | Acetaldehyde dehydrogenase gene RKALDH and application thereof | |
| WO2012037048A1 (en) | Mutant t7 polymerases | |
| Neumann et al. | Reverse genetics of influenza viruses | |
| WO2024099089A1 (en) | Genetically engineered strain for producing pseudouridine, construction method therefor and use thereof | |
| Fernández-Lucas et al. | Lactobacillus reuteri 2′-deoxyribosyltransferase, a novel biocatalyst for tailoring of nucleosides | |
| US10508279B2 (en) | Recombinant Escherichia coli for high efficiency production of fructosylated chondroitin and method for making thereof | |
| CN105296454A (en) | Alginate lyase gene algp and its preparation method and expression | |
| CN113151378B (en) | Method for preparing nicotinic acid or its derivative nucleoside, nicotinic acid adenine dinucleotide, nicotinic acid mononucleotide, enzyme composition and application | |
| CN114317386A (en) | Gene engineering strain for producing inosine and construction method and application thereof | |
| CN106636033A (en) | Improved cell-free synthesis system and application thereof | |
| CN102776217B (en) | Biosynthesis method for increasing accumulation of L-5-methyltetrahydrofolate | |
| CN107043756A (en) | A kind of method that skeletal muscle receptor tyrosine kinase is prepared by cell free, protein synthesizing system | |
| WO2017148163A1 (en) | Method for extracting 2',3'-cyclic nucleoside monophosphates | |
| CN108715828B (en) | A method for establishing a model of programmed necrosis of porcine intestinal epithelial cells induced by DON | |
| CN106754998A (en) | A kind of method of gene and its expressing protein | |
| CN102337288A (en) | Gene engineering preparation method of tilapia hepcidin | |
| CN103882045B (en) | Bacterial strain of producing pyruvic acid and construction method of bacterial strain | |
| CN108070592A (en) | Small interfering RNA expression system for producing small interfering RNA and application thereof | |
| CN102703400A (en) | Hot start DNA (Deoxyribose Nucleic Acid) polymerase and application thereof | |
| CN102816232B (en) | Peanut 2s-4b protein and production method thereof | |
| CN106801047A (en) | A kind of method that cysteine proteinase is prepared by cell free, protein synthesizing system | |
| CN105524955B (en) | A kind of method that bioanalysis prepares theobromine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |